Amicus Therapeutics, Inc. (NASDAQ:FOLD)‘s stock had its “buy” rating reiterated by equities research analysts at Chardan Capital in a research note issued on Thursday, October 5th. They presently have a $18.50 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $16.50. Chardan Capital’s price target suggests a potential upside of 26.37% from the stock’s previous close.
Several other research analysts have also recently weighed in on FOLD. BidaskClub cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 11th. J P Morgan Chase & Co reissued an “overweight” rating and set a $15.00 price objective (up from $13.00) on shares of Amicus Therapeutics in a report on Wednesday, August 9th. Cowen and Company reissued a “buy” rating and set a $16.00 price objective on shares of Amicus Therapeutics in a report on Monday, August 14th. Robert W. Baird upped their target price on shares of Amicus Therapeutics from $12.00 to $15.00 and gave the company an “outperform” rating in a report on Wednesday, July 12th. Finally, Leerink Swann reaffirmed a “buy” rating and set a $20.00 target price (up from $17.00) on shares of Amicus Therapeutics in a report on Wednesday, October 4th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $17.81.
Shares of Amicus Therapeutics (NASDAQ:FOLD) opened at 14.64 on Thursday. The stock’s 50 day moving average is $14.39 and its 200 day moving average is $10.90. The stock’s market cap is $2.41 billion. Amicus Therapeutics has a 52 week low of $4.41 and a 52 week high of $16.60.
Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.03. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. The firm had revenue of $7.16 million during the quarter, compared to analysts’ expectations of $6.96 million. During the same period in the previous year, the company earned ($0.40) earnings per share. On average, equities analysts forecast that Amicus Therapeutics will post ($1.32) EPS for the current year.
In other news, SVP Daphne Quimi sold 7,000 shares of the stock in a transaction on Thursday, October 12th. The shares were sold at an average price of $14.25, for a total value of $99,750.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO John F. Crowley sold 449,295 shares of the stock in a transaction on Monday, October 16th. The stock was sold at an average price of $14.33, for a total transaction of $6,438,397.35. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 556,489 shares of company stock valued at $7,965,912. 3.40% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Teacher Retirement System of Texas increased its stake in shares of Amicus Therapeutics by 1.7% in the second quarter. Teacher Retirement System of Texas now owns 10,243 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 169 shares in the last quarter. DORCHESTER WEALTH MANAGEMENT Co purchased a new stake in shares of Amicus Therapeutics in the second quarter worth $111,000. Tudor Investment Corp ET AL purchased a new stake in shares of Amicus Therapeutics in the second quarter worth $124,000. Aperio Group LLC increased its stake in shares of Amicus Therapeutics by 13.5% in the second quarter. Aperio Group LLC now owns 13,986 shares of the biopharmaceutical company’s stock worth $141,000 after purchasing an additional 1,663 shares in the last quarter. Finally, Zacks Investment Management bought a new position in shares of Amicus Therapeutics during the second quarter worth $145,000.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with our FREE daily email newsletter.